Treatment of XXXX with @entity801 once or three times daily.

@entity1 @entity801 @entity4658 @entity2167 @entity3542 @entity281 @entity2794 @entity2885 @entity221 @entity293 @entity526
AIM: To examine the safety and efficacy of @entity2794 ( @entity2794 ) @entity801 treatment compared with conventional 8-hourly dosing (TDS) for @entity293 ( @entity293 ). METHODS: This was a prospective, randomized, controlled trial of @entity1 1 mo to 13 y of age with presumed @entity293 . @entity1 were randomly assigned to @entity2794 @entity801 5 mg kg(-1) d(-1) or TDS @entity801 6 mg kg(-1) d(-1) divided 8 hourly. Microbiological efficacy, nephrotoxicity, @entity2167 and renal scarring were assessed at the end of treatment. RESULTS: 210 @entity1 with presumed @entity293 were recruited, of whom 172 were analysable ( @entity2794 84, TDS 88). The median age was 7 mo, 50% were male and 74% (n = 127) of @entity1 had @entity2885 . The majority of @entity281 were due to @entity526 (n = 153, 89%), of which 9 (5.2%) were bacteraemic. Comparing the two groups, there was no significant difference in age, gender, duration of fever before admission, @entity4658 , @entity3542 positivity or initial total white blood cell count. All @entity1 had negative urine cultures after 2-3 d of treatment, demonstrating 100% microbiological efficacy. There was no difference between the two groups in terms of @entity2167 , nephrotoxicity, duration of @entity801 treatment or time to @entity221 . CONCLUSION: @entity2794 @entity801 is as efficacious as TDS @entity801 in the treatment of @entity293 in @entity1 , with no difference in @entity2167 and nephrotoxicity.
